CJC-1295: How It Works, What It's Studied For & Safety
CJC-1295 is a growth-hormone-releasing-hormone (GHRH) analog studied for sustained stimulation of the body's own pulsatile GH and IGF-1 release. Clinicians consider it for endogenous growth-hormone axis support in adults. It is not FDA-approved as a finished drug product and is dispensed by Wells Pharmacy Network only after a licensed clinician evaluates intake, history, and labs.
Also known as: Modified GRF (1-29), DAC:GRF
How does CJC-1295 work?
CJC-1295 is a synthetic GHRH (1-29) analog modified to resist enzymatic degradation. The DAC (drug-affinity-complex) version covalently binds plasma albumin, dramatically extending its half-life and producing prolonged, low-amplitude elevation in GH and IGF-1 - distinct from exogenous HGH administration.
What is CJC-1295 studied for?
- Endogenous growth-hormone axis support in adults
- Pairing with growth-hormone secretagogues (Ipamorelin, Hexarelin) in body-composition protocols
- Sleep architecture research where slow-wave sleep is the target
How is CJC-1295 taken?
Compounded as a subcutaneous injection. Non-DAC ('Mod GRF 1-29') is dosed multiple times per week; DAC versions are dosed weekly. Clinician-directed cycles run several months with periodic IGF-1 monitoring.
Is CJC-1295 FDA-approved? Is it safe?
Not FDA-approved for the prevention, treatment, or cure of any condition. Used inside research-informed, clinician-directed protocols only. Common research-reported effects include injection-site reactions and transient flushing. Not appropriate for patients with active malignancy or untreated diabetic retinopathy. Compounded prescription-only preparations are dispensed by Wells Pharmacy Network. Eligibility is decided by a licensed clinician based on intake and labs, not by checkout. Compounded products on this site are not FDA-approved and are not generic equivalents of any branded medication.
In the Regen Therapy catalog
The protocols below are dispensed by Wells Pharmacy Network and contain CJC-1295. Each one is prescribed only after a clinician evaluation.
What does the research say about CJC-1295?
Phase-1 and phase-2 pharmacology in healthy adults established the dose-dependent, sustained IGF-1 elevation profile; no FDA approval for adult GH-axis support exists.
Citations & further reading
Considering CJC-1295 as part of a protocol?
Browse Regen Therapy's catalog or start a clinician evaluation. Every prescription is reviewed by a licensed clinician and dispensed by Wells Pharmacy Network.
Browse the catalog →